IMPAACT4TB August Newsletter

No #EndAIDS without #EndTB

From 20-24 July 2019, members of the IMPAACT4TB Consortium were in Mexico City, where they joined hundreds of other delegates in discussing the links between HIV and TB, and the implications of TB prevention for people living with HIV.

Civil society involvement

The Treatment Action Group (TAG) is supporting global and national advocacy by civil society and community-based organizations to scale-up TB Preventive Therapy and pediatric TB interventions. Find out more about partners working across the 12 project countries.

A guide to rifapentine

In April, the Treatment Action Group (TAG) released a new guide that includes important efficacy, safety and access information on rifapentine, a game-changing drug that forms the backbone of newer regimens—including 3HP—for preventing active TB disease.

Global Fund and PEPFAR support

The Global Fund and PEPFAR are committed to TB Preventive Therapy for PLHIV and household contacts of active TB cases, especially children under 5 years of age. Recently, the Global Fund established new mechanisms to allow countries—starting with South Africa—to deploy 3HP.

Countries gear up for 3HP introduction

Preparation towards the implementation of 3HP in project countries has already begun. Following the UN High-Level Meeting on TB last year and updated WHO guidelines, ministries of health are updating their national plans to include short course preventative therapies, including 3HP.

Announcements & Updates

Catalyzing Pediatric TB Innovations: New brief reviews the benefits of new, shorter regimens for children, including 3HP versus 3HR.

DTG and pregnancy: New studies and WHO guidance clarify the way forward for use of dolutegravir in women of childbearing age.

Op-ed: This kills more South Africans than any other disease. ‘There’s a new way to stop it.’ Read a piece published in the Mail & Guardian by Aurum’s CEO, Gavin Churchyard.

Read the ‘Declaration on the Rights of People Affected by TB’.